A comprehensive view of Alnylam Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
Published: April 07, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Roche and Alnylam report successful Phase 2 trial of zilebesiran, showing significant blood pressure reductions in treated adults with mild to moderate uncontrolled hypertension; the study supports potential for twice-yearly dosing
Published: March 05, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Alnylam presents positive results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension in patients at high cardiovascular risk
Published: November 11, 2023 by F. Hoffmann-La Roche Ltd. (Roche)
Roche and Alnylam's Zilebesiran injectable meets primary and key secondary endpoints in Phase 2 KARDIA-1 study, demonstrating significant blood pressure reduction in adults with hypertension; full results to be presented at upcoming scientific conference
Published: September 07, 2023 by GlobeNewswire Europe
Alnylam Pharmaceuticals plans to appeal Delaware Court ruling on patent dispute with Moderna; Alnylam's separate patent infringement contentions against Pfizer unaffected by this ruling
Published: August 26, 2023 by CE Noticias Financieras (Latin America)

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count